Recently, a phase II multicentre, double-blind, randomized controlled trial including 338 adults with obesity were administered retatrutide (1, 2 mg starting dose increased to 4, 2 mg starting dose increased to 8, 2 mg starting dose increased to 12 mg) compared to placebo over 48 weeks [64]
To get it into a swallowable tablet, Novo Nordisk pairs the drug with an absorption helper called SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate)
Why Youre Considering This in the First Place People dont seek out GLP-1 therapy because they lack discipline or motivation
How is dosing determined
TRULICITY 1.5 mg solution for injection in pre-filled pen SmPC
Future obesity treatment may segment patients by metabolic phenotype, comorbidities, weight-loss targets, liver fat burden, cardiovascular risk, and treatment tolerance